ArticleInternational journal of laboratory hematology2026
Concordance Between Fragment Analysis and Next-Generation Sequencing in Identification of Non-Standard CALR Indels.
Article in International journal of laboratory hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesIdentification of CALR indels is key in the diagnosis of myeloproliferative neoplasms (MPNs) that are JAK2 or MPL wild-type. Most patients harbor either type 1 (52-bp deletion) or type 2 (5-bp insertion) exon 9 indels, both of which produce a +1 frameshift and loss of the KDEL ER-retention motif. Additional indels have been characterized. However, many still present diagnostic challenges in interpretation, especially when relying on fragment size alone. Our goal was to assess the concordance of detection of rare CALR indels using two available molecular diagnostic assays in the diagnosis of MPN.
methodsWe reviewed 6 years of CALR exon 9 testing at our institution, focusing on patients with non-type 1/type 2 indels (non-standard). Fragment sizing was performed by PCR with capillary electrophoresis (PCR-CE), with a subset reflexed to next-generation sequencing (NGS) for clarification. We assessed reading frame shifts, KDEL motif status, variant allele frequencies (VAFs), and co-occurring mutations where available.
resultsOver a 6-year period, a total of 3474 CALR tests were performed, with indels being detected in 125 patients. Forty patients with exon 9 CALR indels other than 52 bp-del and 5 bp-ins were identified (40/125; 32%). Among these, the most frequently detected indel was the 9-bp deletion (19/125; 15.2%). Parallel NGS reports were available in 11 patients. From these, five showed a discrepant indel size (5/11 = 45%) between PCR-CE and NGS by ±1 or -2-bp. These discrepancies resulted in novel frameshifts that were originally categorized as in-frame indels by PCR-CE.
conclusionsPCR-CE should be used as a screening method, and indels other than 52-bp del or 5-bp ins should prompt reflex NGS testing to determine frame and clonal status. These findings establish an opportunity to standardize molecular testing for CALR testing in patients with suspected MPN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.